• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 69-83 of 313 results

22 Notice of Deposition: Notice of Deposition of Leon H Kircik, MD

Document IPR2019-00207, No. 22 Notice of Deposition - Notice of Deposition of Leon H Kircik, MD (P.T.A.B. Sep. 20, 2019)
Notice of Deposition of Leon H. Kircik, MD
PLEASE TAKE NOTICE that pursuant to 37 C.F.R. § 42.53, Petitioners Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC, hereby provide notice to Patent Owner Almirall, LLC that the deposition of Leon H. Kircik, MD will be held on Friday, October 4, 2019, beginning at 9:00 AM, at the offices of Fenwick & West, LLP, located at 902 Broadway, Suite 14, New York, NY 10010-6035.
The deposition will be recorded using audiotape and/or stenographic means pursuant to 37 C.F.R. § 42.53(a).
The deposition will also be transcribed by real-time reporting software.
Lead Attorney for Petitioners Registration No. 61,868 CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e)) The undersigned hereby certifies that the “Notice of Deposition of Leon H. Kircik, MD” was served in its entirety on September 20, 2019, via electronic mail upon the following counsel for Patent Owner:
cite Cite Document
Analyze

9 Preliminary Response: Patent Owners Preliminary Response

Document IPR2019-01095, No. 9 Preliminary Response - Patent Owners Preliminary Response (P.T.A.B. Sep. 10, 2019)
Additionally, although “an objective of the AIA is to provide an effective and efficient alternative to district court litigation, ... [there is a] potential for abuse of the review process by repeated attacks on patents.” Id. at 16–17.
Amneal has filed an ANDA seeking approval to engage in commercial manufacture of a generic dapsone gel, 7.5% drug product prior to the expiration of the Orange Book-listed ʼ219 patent.
In Abiomed 2, the Board found that “[t]his factor weighs heavily in our analysis because Petitioner tailored its arguments here in light of the positions previously set forth by Patent Owner in its preliminary responses in the related proceedings.
As the Petitioner in this case likewise relies upon not just similar, but identical references and used the prior filings as guidance, Factor 3 also weighs heavily in favor of denying institution in this proceeding.
27, 2015) (“Petitioner could have informed the Board of its desire to challenge the additional claims along with the [original IPR] well before [the joinder deadline], yet it chose to file its Second Petition on the very last day permitted under the rules.”).
cite Cite Document
Analyze

21 Objection: Petitioners Objections to Evidence

Document IPR2019-00207, No. 21 Objection - Petitioners Objections to Evidence (P.T.A.B. Aug. 16, 2019)
Log in to see more
cite Cite Document
Analyze

20 Response: Patent Owners Response to Petition for Inter Partes Review

Document IPR2019-00207, No. 20 Response - Patent Owners Response to Petition for Inter Partes Review (P.T.A.B. Aug. 9, 2019)
Log in to see more
cite Cite Document
Analyze

19 Notice: Notice of Stipulation to Extend Due Dates 1, 2, and 3

Document IPR2019-00207, No. 19 Notice - Notice of Stipulation to Extend Due Dates 1, 2, and 3 (P.T.A.B. Jul. 24, 2019)
Log in to see more
cite Cite Document
Analyze

18 Notice of Deposition: Patent Owner Almirall, LLCs Notice of Deposition of Dr Bozena B Michniak Kohn Under CFR Section 4253

Document IPR2019-00207, No. 18 Notice of Deposition - Patent Owner Almirall, LLCs Notice of Deposition of Dr Bozena B Michniak Kohn Under CFR Section 4253 (P.T.A.B. Jul. 17, 2019)
Log in to see more
cite Cite Document
Analyze

17 Notice of Deposition: Patent Owner Almirall, LLCs Notice of Deposition of Dr Elaine S Gilmore Under CFR Section 4253

Document IPR2019-00207, No. 17 Notice of Deposition - Patent Owner Almirall, LLCs Notice of Deposition of Dr Elaine S Gilmore Under CFR Section 4253 (P.T.A.B. Jul. 17, 2019)
Log in to see more
cite Cite Document
Analyze

3 Petition: Petition

Document IPR2019-00207, No. 3 Petition - Petition (P.T.A.B. Nov. 6, 2018)
Log in to see more
cite Cite Document
Analyze

7 Power of Attorney: Patent Owner Almirall, LLCs Power of Attorney

Document IPR2019-01095, No. 7 Power of Attorney - Patent Owner Almirall, LLCs Power of Attorney (P.T.A.B. Jun. 28, 2019)
Patent Owner Power of Attorney / Date: ~ · Name: Ron Menezes Title: President and General Manager, Almirall, LLC
Almirall, LLC, a limited liability company, states that, for the patent identified above, it is the assignee of the entire right, title, and interest.
From: Inventors Bhatt & Swaminathan To: Dow Phannaceutical Sciences The document was recorded in the United States Patent and Trademark Office at Reel 038398, Frame 0200.
From: Inventors Batt & Swaminathan To: Dow Pharmaceutical Sciences The document was recorded in the United States Patent and Trademark Office at Reel 038398, Frame 0001.
From: Allergan, Inc. To: Almirall, LLC The document was recorded in the United States Patent and Trademark Office at Reel 047132, Frame 0642.
cite Cite Document
Analyze

6 Mandatory Notice: Patent Owner Almirall, LLCs Mandatory Notices Under 37 CFR Section 4210b

Document IPR2019-01095, No. 6 Mandatory Notice - Patent Owner Almirall, LLCs Mandatory Notices Under 37 CFR Section 4210b (P.T.A.B. Jun. 28, 2019)
Pursuant to 37 C.F.R. § 42.8, Patent Owner, Almirall, LLC (“Almirall”), hereby files its Mandatory Notices: A. Real Party-In-Interest Under 37 C.F.R. § 42.8(b)(1) The real party-in-interest is Almirall, LLC, a Pennsylvania limited liability company.
The ʼ219 Patent is also the subject of Almirall, LLC v. Amneal Pharmaceuticals LLC, Civil Action No. 19-658 (LPS) in the United States District Court for the District of Delaware, filed April 9, 2019.
37 C.F.R. § 42.8(b)(4) – Service Information Almirall may be served through its counsel, Fenwick & West LLP, at the above-indicated postal and email addresses.
Power of Attorney Filed concurrently with these Mandatory Notices is a Power of Attorney from Patent Owner Almirall to the above-designated counsel at Fenwick & West LLP to transact all business in the United States Patent and Trademark Office in connection with the above-referenced Inter Partes Review.
The Power of Attorney is accompanied by a Statement Under 37 C.F.R. § 3.73(c), executed by Almirall.
cite Cite Document
Analyze

4 Power of Attorney: POA

Document IPR2019-01095, No. 4 Power of Attorney - POA (P.T.A.B. Jun. 7, 2019)

cite Cite Document
Analyze

2 Petition: Petitioners Motion For Joinder Under 37 CFR 4222 AND 42122b

Document IPR2019-01095, No. 2 Petition - Petitioners Motion For Joinder Under 37 CFR 4222 AND 42122b (P.T.A.B. Jun. 7, 2019)

cite Cite Document
Analyze

3 Exhibit List: Exhibit List

Document IPR2019-01095, No. 3 Exhibit List - Exhibit List (P.T.A.B. Jun. 7, 2019)

cite Cite Document
Analyze

8 Preliminary Response: Patent Owners Preliminary Response

Document IPR2019-00207, No. 8 Preliminary Response - Patent Owners Preliminary Response (P.T.A.B. Feb. 14, 2019)

cite Cite Document
Analyze

7 Mandatory Notice: Patent Owner Almirall, LLCs Updated Mandatory Notices Unde...

Document IPR2019-00207, No. 7 Mandatory Notice - Patent Owner Almirall, LLCs Updated Mandatory Notices Under 37 CFR Section 428 (P.T.A.B. Feb. 14, 2019)

cite Cite Document
Analyze
<< 1 2 3 4 5 6 7 8 9 ... >>